Fig. 1: SMYD3 was overexpressed and associated with aggressive behaviors in hepatocellular carcinoma (HCC) tissues.
From: SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters
A Reverse transcription-polymerase chain reaction (RT-PCR) analysis of SMYD3 mRNA expression levels in paired HCC and adjacent noncancerous tissues from 16 patients. B Quantitative real-time polymerase chain reaction (qRT-PCR) analysis of SMYD3 mRNA expression levels in 80 paired HCC and adjacent noncancerous tissue samples. C Immunohistochemistry (IHC) analysis of SMYD3 expression in 10 normal liver samples and 148 pairs of HCC and adjacent noncancerous tissue samples. D Correlations between SMYD3 expression and the clinicopathological characteristics of patients with HCC were determined using the chi-square test. SMYD3-negative was defined as an IHC score ≤4; SMYD3-positive was defined as an IHC score >4. E Kaplan-Meier analysis of overall survival in 148 patients with HCC stratified by SMYD3 expression. The median expression level was used as the cut-off. Low SMYD3 expression in each of the 148 patients was defined as a value below the 50th percentile. High SMYD3 expression in each of the 148 patients was defined as a value above the 50th percentile. F, G Expression of the SMYD3 mRNA and protein in different HCC cell lines. Bar = 200 μm. Data are presented as the means ± SD of three separate experiments, each performed in triplicate. *P < 0.05; **P < 0.01.
